Viatris announced during its Q1 2021 earnings call that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021. These are proposed biosimilars of Sanofi’s LANTUS and Novo Nordisk’s NOVOLOG/NOVORAPID products, respectively. If approved, Viatris’s insulin products would…
